Feed EFTR
Summary
No overall score for this company yet.
Valuation -Growth -Profitability -Quality 0Debt 23Stability 1
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- It passes only 2 of the 9 points of the Piotroski financial health test.
- The price moves much more than the market (beta 2.48).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Is it growing?
Revenue (USD)
201920202021202220232025
Diluted EPS (USD)
2019202020212022202320252026
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $25.4M
Debt $20.2M
It holds more cash than debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 0
Today's price within the analysts' price targets
Today's price $0.0008 Average target $5.5
$0.0008 $10
The average target of $5.5 is 687,400% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2021By product
- Grant Revenue 100%
By region
The company reports no revenue by region.
Grant Revenue brings in 100% of revenue.
Segments in detail